The real-world experience with nivolumab in previously treated patients with advanced non-small cell lung cancer from a cancer center in India

BACKGROUND: PDL-1 inhibitors have emerged as the new standard of care for second line treatment of NSCLC. METHODS: Eligible patients included, histologically proven NSCLC, ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1 or 2, age 18 years and above, availability of pre-treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbas, Waseem, Acharya, Rudra Prasad, Pandit, Archit, Gupta, Saurabh, Rao, Ranga Raju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
ORIGINAL ARTICLE: Lung Cancers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956575/
https://www.ncbi.nlm.nih.gov/pubmed/31956623
http://dx.doi.org/10.4103/sajc.sajc_111_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956575/
https://www.ncbi.nlm.nih.gov/pubmed/31956623
http://dx.doi.org/10.4103/sajc.sajc_111_19

Ejemplares similares